Trials / Completed
CompletedNCT02304419
A Study of Galunisertib on the Immune System in Participants With Cancer
Phase 1 Study to Determine the Immunomodulatory Activity of LY2157299 Monohydrate in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about how the study drug called galunisertib affects the immune system in participants with cancer. The study treatment is expected to last about six months for each participant, not including screening or follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galunisertib | Administered orally. |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2014-12-02
- Last updated
- 2016-10-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02304419. Inclusion in this directory is not an endorsement.